Experience with and perceptions of non-prescription anthelmintics for cancer treatments among cancer patients in South Korea: A cross-sectional survey (2022)

Peer-Reviewed Study · Song B, Kim KJ, Ki SH · October 4, 2022

Song B et al., 2022-10-04: Cross-sectional online survey of 86 South Korean cancer patients using non-prescription anthelmintics for cancer: fenbendazole had been taken by 52.3% of them, 96.5% of those on chemotherapy did not tell their clinicians, and 79.1% believed the drugs were helping.

This survey included 86 cancer patients, aged 19 years and older, who underwent anthelmintic therapy for cancer.

Abstract

Song B et al., 2022-10-04: Cross-sectional online survey of 86 South Korean cancer patients using non-prescription anthelmintics for cancer: fenbendazole had been taken by 52.3% of them, 96.5% of those on chemotherapy did not tell their clinicians, and 79.1% believed the drugs were helping. Study type: cross-sectional online questionnaire survey, n=86, South Korea, recruited from two online cancer communities; all had advanced disease and most started in 2019. Agents used (survey question 7): ivermectin 62.8%, albendazole 60.5%, fenbendazole 52.3%, mebendazole 48.8%, niclosamide 34.9%, nitazoxanide 16.3%; average three agents per patient, maximum eight. Dosing: 62.8% used a Tippens-style cycle of consecutive days then a drug holiday; 58.1% dosed twice daily; average duration 10.5 months. Outcome measure: patient-reported perception only – 79.1% positive, more than two-thirds reported no adverse effects; the authors state there were no medical data to evaluate outcomes. Funding: author contributions list 'Funding acquisition' for Ki Sung Hwan but no funder statement was located in the extracted article text. Declared conflicts: 'The authors have declared that no competing interests exist.' Comparator: none. Limitation stated by the authors: exact dosages unknown because the questionnaire used multiple-choice items. Study type: other.